📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Anokion

1.1 - Company Overview

Anokion Logo

Anokion

Headquarter: Switzerland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of antigen-specific immune tolerance solutions, including an engineered-protein platform for targeted autoimmune therapy without broad immunosuppression; liver-targeting technology to modulate inflammatory responses in antigen-mediated autoimmune diseases; antigen-specific vaccines to prevent reactions to self-antigens; and clinical research services to develop and test new therapies, reducing therapeutic protein immunogenicity.

Products and services

  • Liver Targeting Technology: A receptor-targeted system that targets receptors on liver cells to modulate harmful inflammatory immune responses in antigen-mediated autoimmune diseases
  • Immune Tolerance Platform: A proprietary platform using engineered proteins to deliver targeted therapy for autoimmune diseases without broad immunosuppression, and to reduce the immunogenicity of therapeutic proteins via antigen-specific tolerance
  • Antigen-Specific Vaccines: Self-antigen–directed products that educate the immune system to recognize specific self-antigens as harmless, preventing an inflammatory response by promoting antigen-specific immune tolerance

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Anokion

Sucampo Pharmaceuticals Logo

Sucampo Pharmaceuticals

HQ: United States Website
  • Description: Provider of specialized biopharmaceuticals addressing unmet medical needs, with marketed products AMITIZA for chronic constipation and IBS-C in adults and RESCULA in Japan for lowering intraocular pressure in glaucoma or ocular hypertension, and a late-stage pipeline including VTS-270 for Niemann-Pick Disease Type C and CPP-1X/sulindac for Familial Adenomatous Polyposis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Sucampo Pharmaceuticals company profile →
Evommune Logo

Evommune

HQ: United States Website
  • Description: Provider of therapeutics to halt progressive disease and address symptoms, focused on chronic inflammatory diseases. Develops EVO756, an oral, highly selective MRGPRX2 inhibitor for chronic spontaneous urticaria despite H1 antihistamines; a PKCθ inhibitor to regulate immune response; collaborative drug discovery with partners like Accutar; and clinical trial programs, including Phase 1 for EVO756.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Evommune company profile →
Genome Diagnostics Logo

Genome Diagnostics

HQ: The Netherlands Website
  • Description: Provider of in vitro diagnostic tests and services, molecular diagnostic kits, analysis software, and education for transplantation and companion diagnostics. Delivers sequencing-based, high-resolution HLA typing for Sanger and NGS, NGSgo workflows, Oxford Nanopore solutions (NGS-Pronto, NGS-Turbo), NGSengine-Turbo software, and chimerism monitoring assays and software (NGStrack, TRKengine).
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Genome Diagnostics company profile →
PureTech Health Logo

PureTech Health

HQ: United States Website
  • Description: Provider of biopharma therapies and platforms, including KarXT for schizophrenia (xanomeline + trospium), LYT-100 (deuterated pirfenidone) for idiopathic pulmonary fibrosis, LYT-200 (anti-galectin-9) for hematological malignancies and solid tumors, SPT-300 (oral allopregnanolone) for neurological and neuropsychiatric conditions, plus Vedanta's microbiome-based oral therapies and Entrega's hydrogel-enabled oral biologics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full PureTech Health company profile →
VYNE Therapeutics Logo

VYNE Therapeutics

HQ: United States Website
  • Description: Provider of late-stage biopharmaceutical therapies for dermatologic and immuno-inflammatory diseases via the InhiBET BET Inhibitor Platform. Offerings include VYN201, a locally administered pan-BD BET inhibitor for vitiligo and other diseases with a soft drug approach, and VYN202, an oral BD2-selective BET inhibitor for moderate-to-severe plaque psoriasis and rheumatoid arthritis.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full VYNE Therapeutics company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Anokion

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Anokion

2.2 - Growth funds investing in similar companies to Anokion

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Anokion

4.2 - Public trading comparable groups for Anokion

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Anokion

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Anokion

What does Anokion do?

Anokion is a provider of antigen-specific immune tolerance solutions, including an engineered-protein platform for targeted autoimmune therapy without broad immunosuppression; liver-targeting technology to modulate inflammatory responses in antigen-mediated autoimmune diseases; antigen-specific vaccines to prevent reactions to self-antigens; and clinical research services to develop and test new therapies, reducing therapeutic protein immunogenicity.

Who are Anokion's competitors?

Anokion's competitors and similar companies include Sucampo Pharmaceuticals, Evommune, Genome Diagnostics, PureTech Health, and VYNE Therapeutics.

Where is Anokion headquartered?

Anokion is headquartered in Switzerland.

How many employees does Anokion have?

Anokion has 1,000 employees 🔒.

When was Anokion founded?

Anokion was founded in 2010 🔒.

What sector and industry vertical is Anokion in?

Anokion is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Anokion

Who are the top strategic acquirers in Anokion's sector and industry

Top strategic M&A buyers and acquirers in Anokion's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Anokion?

Top strategic M&A buyers groups and sectors for Anokion include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Anokion's sector and industry vertical

Which are the top PE firms investing in Anokion's sector and industry vertical?

Top PE firms investing in Anokion's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Anokion's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Anokion's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Anokion's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Anokion include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Anokion's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Anokion?

The key public trading comparables and valuation benchmarks for Anokion include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Anokion for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Anokion with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Anokion's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Anokion with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Anokion's' sector and industry vertical?

Access recent funding rounds and capital raises in Anokion's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Anokion